---
title: "PA GOODDOCTOR (1833) reported a net profit of 380 million yuan last year, an increase of 366.1% year-on-year"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280436684.md"
description: "PA GOODDOCTOR's stock price rose today, opening up 4% to HKD 11.96, with a maximum increase of 10.8%. The latest quote is HKD 12.63, an increase of 9.83%. The company announced its 2025 annual results, with revenue of RMB 5.468 billion, a year-on-year increase of 13.7%; gross profit of RMB 1.772 billion, an increase of 16.3%; and net profit of RMB 380 million, an increase of 366.1%. Citigroup maintains a \"Buy\" rating with a target price of HKD 18"
datetime: "2026-03-25T08:24:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280436684.md)
  - [en](https://longbridge.com/en/news/280436684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280436684.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280436684.md) | [English](https://longbridge.com/en/news/280436684.md)


# PA GOODDOCTOR (1833) reported a net profit of 380 million yuan last year, an increase of 366.1% year-on-year

PA GOODDOCTOR (1833.HK) saw a significant improvement in its stock price today (25th), opening 4% higher at HKD 11.96, and further rising, peaking at a 10.8% increase to HKD 12.74 during the early session. As of the latest quote of HKD 12.63, it has risen 9.83%, with a trading volume of approximately 6.6516 million shares, involving HKD 82.5524 million.

The group simultaneously announced its performance for the fiscal year 2025, with total revenue reaching RMB 5.468 billion, a year-on-year increase of 13.7%; during the period, gross profit recorded RMB 1.772 billion, up 16.3% year-on-year. The profit performance was even more impressive, with a net profit of RMB 380 million for the year, a substantial year-on-year increase of 366.1%; earnings per share were RMB 0.18; adjusted net profit was RMB 414 million, a year-on-year growth of 161.3%.

Citigroup immediately released a research report stating that PA GOODDOCTOR's revenue last year met market expectations, while net profit performance exceeded both market and the bank's original expectations, maintaining a "Buy" rating and setting a target price of HKD 18

### 相關股票

- [PA GOODDOCTOR (01833.HK)](https://longbridge.com/zh-HK/quote/01833.HK.md)

## 相關資訊與研究

- [Jefferies Reaffirms Their Hold Rating on Ping An Healthcare and Technology Company (PANHF)](https://longbridge.com/zh-HK/news/280867231.md)
- [Citi Remains a Buy on Ping An Healthcare and Technology Company (PANHF)](https://longbridge.com/zh-HK/news/274969599.md)
- [Baiyunshan Pharma Gets Approval for Carbocisteine Oral Solution's Registration in Macau](https://longbridge.com/zh-HK/news/281478355.md)
- [Miraval Resorts & Spas and Humin Set New Standard for the Future of Measurable Wellness with Groundbreaking New Study | H Stock News](https://longbridge.com/zh-HK/news/281216315.md)
- [JD Logistics Grants New Employee Share Awards with Robust Clawback Terms](https://longbridge.com/zh-HK/news/281373299.md)